- Home
- NTCT vs KNSA Comparison
NTCT vs KNSA Comparison
Compare NTCT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTCT
- KNSA
- Stock Information
- Founded
- NTCT 1984
- KNSA 2015
- Country
- NTCT United States
- KNSA United Kingdom
- Employees
- NTCT N/A
- KNSA N/A
- Industry
- NTCT EDP Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- NTCT Technology
- KNSA Health Care
- Exchange
- NTCT Nasdaq
- KNSA Nasdaq
- Market Cap
- NTCT 1.7B
- KNSA 2.0B
- IPO Year
- NTCT 1999
- KNSA 2018
- Fundamental
- Price
- NTCT $21.61
- KNSA $26.03
- Analyst Decision
- NTCT Hold
- KNSA Strong Buy
- Analyst Count
- NTCT 1
- KNSA 6
- Target Price
- NTCT $25.00
- KNSA $38.00
- AVG Volume (30 Days)
- NTCT 426.5K
- KNSA 677.6K
- Earning Date
- NTCT 05-08-2025
- KNSA 04-29-2025
- Dividend Yield
- NTCT N/A
- KNSA N/A
- EPS Growth
- NTCT N/A
- KNSA N/A
- EPS
- NTCT N/A
- KNSA N/A
- Revenue
- NTCT $822,679,000.00
- KNSA $481,166,000.00
- Revenue This Year
- NTCT $0.22
- KNSA $37.21
- Revenue Next Year
- NTCT $2.04
- KNSA $1.53
- P/E Ratio
- NTCT N/A
- KNSA N/A
- Revenue Growth
- NTCT N/A
- KNSA 59.45
- 52 Week Low
- NTCT $17.10
- KNSA $17.38
- 52 Week High
- NTCT $27.89
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- NTCT 61.28
- KNSA 63.21
- Support Level
- NTCT $19.98
- KNSA $25.97
- Resistance Level
- NTCT $22.34
- KNSA $28.56
- Average True Range (ATR)
- NTCT 0.64
- KNSA 1.24
- MACD
- NTCT 0.13
- KNSA 0.36
- Stochastic Oscillator
- NTCT 70.45
- KNSA 71.70
About NTCT NetScout Systems Inc.
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.